| Literature DB >> 33192566 |
Nina Dirkx1, Francesco Miceli2, Maurizio Taglialatela2, Sarah Weckhuysen1,3,4.
Abstract
Kv7.2 subunits encoded by the KCNQ2 gene constitute a critical molecular component of the M-current, a subthreshold voltage-gated potassium current controlling neuronal excitability by dampening repetitive action potential firing. Pathogenic loss-of-function variants in KCNQ2 have been linked to epilepsy since 1998, and there is ample functional evidence showing that dysfunction of the channel indeed results in neuronal hyperexcitability. The recent description of individuals with severe developmental delay with or without seizures due to pathogenic variants in KCNQ2 (KCNQ2-encephalopathy) reveals that Kv7.2 channels also have an important role in neurodevelopment. Kv7.2 channels are expressed already very early in the developing brain when key developmental processes such as proliferation, differentiation, and synaptogenesis play a crucial role in brain morphogenesis and maturation. In this review, we will discuss the available evidence for a role of Kv7.2 channels in these neurodevelopmental processes, focusing in particular on insights derived from KCNQ2-related human phenotypes, from the spatio-temporal expression of Kv7.2 and other Kv7 family member, and from cellular and rodent models, highlighting critical gaps and research strategies to be implemented in the future. Lastly, we propose a model which divides the M-current activity in three different developmental stages, correlating with the cell characteristics during these particular periods in neuronal development, and how this can be linked with KCNQ2-related disorders. Understanding these mechanisms can create opportunities for new targeted therapies for KCNQ2-encephalopathy.Entities:
Keywords: KCNQ2; KCNQ2-encephalopathy; Kv7.2; M-current; neurodevelopment
Year: 2020 PMID: 33192566 PMCID: PMC7657400 DOI: 10.3389/fphys.2020.570588
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Figure 1Overview of the effect of different KCNQ2 pathogenic variants on the M-current and their associated clinical phenotype.
Figure 2Schematic overview of KCNQ2 transcript expression during the different phases of neuronal development. Top, showing the different cell types during differentiation; stem cell (left), neuronal progenitor cell (NPC, middle), and neuron (right). Middle, showing the cell characteristics during neuronal development, and its correlation with the M-current density. Bottom, expression profile of the different KCNQ2 transcripts based on the data exported from the LIBD stem cell browser.
Figure 3Kv7.2 and Kv7.3 expression during human brain development. Top, timeline of key neural developmental cellular processes in the human brain (adapted from Semple et al., 2013). Bottom, representation of Kv7.2 and Kv7.3 positive neurons in the temporal lobe and the hippocampus during the three neurodevelopmental phases (adapted from Kanaumi et al., 2008).
Overview of in vitro studies that use pharmacological blockers or openers to chronically block the M-current.
| Cell type | Intervention | Observed effect | References |
|---|---|---|---|
| P0–2 mouse hippocampal CA1 pyramidal neurons | Acute XE991 | Increased the intrinsic excitability | ( |
| Chronic XE991 | Gradual decrease in intrinsic excitability and a distal shift of AIS | ||
| PC12 and P0 rat cortical neurons | Chronic XE991 | Increased neurite outgrowth | ( |
| Chronic retigabine | Decreased neurite outgrowth | ||
| Rat fetal cortical neurons | Chronic linopiridine | Increased excitatory synaptogenesis | ( |
| mESC and mouse embryonic hippocampal neurons | Chronic XE991 or chronic linopirdine | Decreased synaptic and vesicular proteins in inhibitory, but not excitatory neurons | ( |
P0–2, 0–2 days postnatally; CA1, cornu ammonis 1; XE991, 10,10-bis(pyridin-4-ylmethyl)anthracen-9-one; AIS, axon initial segment; PC12, pheochromocytoma 12; mESC, mouse embryonic stem cells.